Acalabrutinib

Phase 1/2Active

0 views this week 0 watching💤 Quiet

Interest: 36/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Phase I: Relapsed or Refractory B-cell Malignancies

Conditions

Phase I: Relapsed or Refractory B-cell Malignancies, Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma, Phase II Cohort B: Relapsed or Refractory Chronic Lymphocytic Leukemia

Trial Timeline

Apr 29, 2020 → Jun 24, 2026

NCT ID

NCT03932331

About Acalabrutinib

Acalabrutinib is a phase 1/2 stage product being developed by AstraZeneca for Phase I: Relapsed or Refractory B-cell Malignancies. The current trial status is active. This product is registered under clinical trial identifier NCT03932331. Target conditions include Phase I: Relapsed or Refractory B-cell Malignancies, Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma, Phase II Cohort B: Relapsed or Refractory Chronic Lymphocytic Leukemia.

What happened to similar drugs?

7 of 15 similar drugs in Phase I: Relapsed or Refractory B-cell Malignancies were approved

Approved (7) Terminated (2) Active (6)

✅Lemborexant + PlaceboEisaiApproved

✅progesterone + ProgesteroneMerckApproved

✅NilotinibNovartisApproved

✅AsciminibNovartisApproved

✅DasatinibBristol Myers SquibbApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (15)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06757647	Phase 2	Recruiting	May 27, 2025	Dec 31, 2027	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT06651970	Approved	Recruiting	Feb 4, 2025	Aug 16, 2030	Chronic Lymphocytic Leukaemia
NCT06205498	Pre-clinical	Active	Aug 8, 2023	Apr 30, 2027	Chronic Lymphocytic Leukemia
NCT05256641	Phase 1/2	Recruiting	Jan 23, 2023	Jan 31, 2028	Diffuse Large B-Cell Lymphoma
NCT05557695	Pre-clinical	Recruiting	Oct 17, 2022	Apr 1, 2027	Chronic Lymphocytic Leukemia, CLL
NCT04660045	Phase 2	Withdrawn	May 1, 2022	Jun 1, 2026	Chronic Lymphocytic Leukemia
NCT05038904	Phase 2	Completed	Dec 16, 2021	Dec 31, 2022	Food Allergy
NCT04198922	Phase 2	Active	Dec 11, 2020	Apr 30, 2027	Recurrent Moderate-Severe Chronic Graft Versus Host Disease
NCT04548648	Phase 2	Active	Oct 15, 2020	Mar 14, 2030	Central Nervous System Lymphoma
NCT04497948	Phase 1	Terminated	Sep 21, 2020	Nov 18, 2020	COVID-19
NCT04380688	Phase 2	Completed	Jun 13, 2020	Nov 16, 2020	COVID-19
NCT04346199	Phase 2	Completed	Jun 12, 2020	Nov 17, 2020	COVID-19
NCT03932331	Phase 1/2	Active	Apr 29, 2020	Jun 24, 2026	Phase I: Relapsed or Refractory B-cell Malignancies
NCT04008706	Phase 3	Completed	Sep 17, 2019	Nov 4, 2025	Chronic Lymphocytic Leukemia
NCT03968848	Phase 1	Completed	Nov 12, 2018	Mar 29, 2019	Hepatic Impairment

Competing Products

20 competing products in Phase I: Relapsed or Refractory B-cell Malignancies

See all competitors

Product	Company	Stage	Hype Score
TERN-701	Terns Pharmaceuticals	Phase 1/2	36
Tamsulosin HCl + Solifenacin Succinate + EC905	Astellas Pharma	Phase 1	29
solifenacin succinate + mirabegron + mirabegron/solifenacin succinate	Astellas Pharma	Phase 1	29
Graceptor®	Astellas Pharma	Pre-clinical	26
Lemborexant + Placebo	Eisai	Approved	50
BIW-8962	Kyowa Kirin	Phase 1/2	24
Sacituzumab tirumotecan	Merck	Phase 2	42
progesterone + Progesterone	Merck	Approved	39
Asciminib	Novartis	Pre-clinical	30
Nilotinib	Novartis	Phase 3	40
Imatinib mesylate	Novartis	Phase 3	32
Imatinib Mesylate 600 MG Oral Tablet + Imatinib Mesylate 400 MG Oral Tablet + Imatinib Mesylate	Novartis	Phase 3	32
ribociclib + Trametinib	Novartis	Phase 1	21
Nilotinib	Novartis	Approved	43
Imatinib	Novartis	Phase 3	40
Nilotinib	Novartis	Approved	43
Gleevec	Novartis	Phase 2	35
Nilotinib + Ruxolitinib	Novartis	Phase 1/2	32
ABL001	Novartis	Phase 3	40
asciminib	Novartis	Phase 2	39